Read by QxMD icon Read

dermatomyositis meta

Liubing Li, Qian Wang, Xiaoting Wen, Chenxi Liu, Chanyuan Wu, Funing Yang, Xiaofeng Zeng, Yongzhe Li
Anti-melanoma differentiation-associated protein 5 (MDA5) antibody have been found in dermatomyositis (DM)-associated interstitial lung disease (DM-ILD) and DM-associated rapidly progressive ILD (DM-RPILD). Due to the conflicting results regarding the association between anti-MDA5 antibody and DM-ILD or DM-RPILD and the diagnostic value of this antibody for DM-ILD and DM-RPILD, we performed this meta-analysis. A systematic search was performed to identify studies published to January 14, 2017. Sixteen publications with 491 DM with ILD versus 605 DM without ILD, as well as eighteen publications with 186 DM with RPILD and 790 DM without RPILD were included...
July 6, 2017: Oncotarget
Paulius Venalis, Sandra Selickaja, Karin Lundberg, Rita Rugiene, Ingrid E Lundberg
OBJECTIVES: An association between cancer and dermatomyositis (DM) is well recognized. The high frequency of malignancies detected close to DM diagnosis suggests that DM can be a paraneoplastic syndrome. Recently anti-TIF1-gamma has been discovered to be associated with cancer and DM. A meta-analysis claimed pooled sensitivity of anti-p155 for diagnosing cancer-associated DM to be 78% and specificity to be 89%. Thus anti-TIF1-gamma has shown promising results as a marker forcancer-associated DM ...
July 13, 2017: Arthritis Care & Research
Young Ho Lee, Gwan Gyu Song
This study aimed at analyzing published data on the association between idiopathic inflammatory myopathy and venous thromboembolism (VTE). We examined studies on VTE risk in patients with polymyositis (PM) and/or dermatomyositis (DM), in the MEDLINE, EMBASE, and Cochrane databases and via manual searches. We performed a meta-analysis on the relative risks (RRs) of VTE, pulmonary embolism (PE), and deep vein thrombosis (DVT) in these patients. Five studies, including 8858 patients with PM/DM met the inclusion criteria...
July 2017: Rheumatology International
Hiroyuki Kamiya, Ogee Mer Panlaqui, Shinyu Izumi, Takashi Sozu
INTRODUCTION: Idiopathic inflammatory myopathies may be an overlapping disease complex. Although interstitial lung disease affects the mortality and the morbidity of the disease, a clinical course and the prognosis of the disease complicated with interstitial lung disease are diverse among individuals and prognostic factors have yet to be clarified. This article aims to report the rationale and the methodology of a future intended systematic review and meta-analysis of prognostic factors of idiopathic inflammatory myopathies complicated with interstitial lung disease...
November 17, 2016: BMJ Open
Judy K Qiang, Whan B Kim, Akerke Baibergenova, Raed Alhusayen
BACKGROUND: There is variation in the risk of malignancy in dermatomyositis (DM) and polymyositis (PM) in the existing literature. OBJECTIVE: To conduct a meta-analysis to estimate the risk of malignancy in DM and PM as compared with the general population. METHODS: Medline and Embase Database abstracts were searched through August 2014 using the search terms myositis, neoplasms, and paraneoplastic syndromes. Population-based, observational studies in English were included...
March 2017: Journal of Cutaneous Medicine and Surgery
Li Zhang, Guoqin Wu, Di Gao, Guijian Liu, Lin Pan, Liyan Ni, Zheng Li, Qiang Wang
OBJECTIVES: Interstitial lung disease (ILD) is an extramuscular manifestation that results in increased morbidity and mortality from polymyositis (PM) and dermatomyositis (DM). The aim of this study was to systematically evaluate risk factors associated with the development of ILD in PM/DM. METHODS: Observational studies were identified from searching PubMed, Medline, Embase, and the Cochrane Library. Pooled odds ratios (ORs) or standardized mean differences (SMDs) and corresponding 95% confidence intervals (CIs) were obtained for the relationships between risk factors and ILD in PM/DM using either fixed- or random-effects models, whichever were appropriate...
2016: PloS One
Naruemon Bamrungsawad, Nathorn Chaiyakunapruk, Nilawan Upakdee, Chayanin Pratoomsoot, Rosarin Sruamsiri, Piyameth Dilokthornsakul
INTRODUCTION: Intravenous immunoglobulin (IVIG) has been shown to be effective in treating steroid-refractory dermatomyositis (DM). There remains no evidence of its cost-effectiveness in Thailand. OBJECTIVE: Our objective was to estimate the cost utility of IVIG as a second-line therapy in steroid-refractory DM in Thailand. METHODS: A Markov model was developed to estimate the relevant costs and health benefits for IVIG plus corticosteroids in comparison with immunosuppressant plus corticosteroids in steroid-refractory DM from a societal perspective over a patient's lifetime...
May 2015: PharmacoEconomics
Jeannette M Olazagasti, Pedro J Baez, David A Wetter, Floranne C Ernste
BACKGROUND: An association between dermatomyositis (DM) and cancer has been reported since 1916; however, estimates of the associated risk vary widely. For cost-effectiveness reasons it might be important to elucidate the degree of overall cancer risk in DM. OBJECTIVE: The aim of this systematic review was to investigate the association of cancer in DM by performing a meta-analysis of cohort studies. DATA SOURCES: A systematic literature search of PubMed, Ovid MEDLINE, EMBASE, Web of Science, Scopus, and the Cochrane Collaboration was conducted without language restriction, to 1 May 2014...
April 2015: American Journal of Clinical Dermatology
Patompong Ungprasert, Wisit Cheungpasitporn, Karn Wijarnpreecha, Wasin Ahuja, Praveen Ratanasrimetha, Charat Thongprayoon
Several chronic inflammatory disorders, such as rheumatoid arthritis and systemic lupus erythematosus, have been demonstrated to increase ischemic stroke risk, but the data on polymyositis (PM) and dermatomyositis (DM) remain unclear. We conducted a systematic review and meta-analysis of observational studies that reported odds ratio, relative risk, hazard ratio or standardized incidence ratio comparing ischemic risk in patients with PM/DM versus non-PM/DM participants. Pooled risk ratio and 95 % confidence intervals were calculated using a random-effect, generic inverse variance method of DerSimonian and Laird...
May 2015: Rheumatology International
Si Chen, Qian Wang, Ziyan Wu, Qingjun Wu, Ping Li, Yuan Li, Jing Li, Chuiwen Deng, Chanyuan Wu, Lei Gao, Fengchun Zhang, Yongzhe Li
BACKGROUND: Some surveys had inspected the effects of the tumor necrosis factor-α (TNF-α)-308A/G polymorphism on susceptibility to dermatomyositis (DM), and showed mixed results. To briefly review these consequences, a comprehensive meta-analysis was carried out to estimate the relationship between them much more accurately. METHODS: Relevant documents dated to February 2014 were acquired from the PUBMED, MEDLINE, and EMBASE databases. The number of the genotypes and/or alleles for the TNF-α-308A/G in the DM and control subjects was extracted and statistical analysis was conducted using STATA 11...
2014: PloS One
Xin Lu, Hanbo Yang, Xiaoming Shu, Fang Chen, Yinli Zhang, Sigong Zhang, Qinglin Peng, Xiaolan Tian, Guochun Wang
OBJECTIVE: To define potential factors that could predict concomitant neoplastic diseases in patients diagnosed with PM/DM, which could inform screening decisions. METHODS: Two researchers independently reviewed articles from Pubmed (MEDLINE), EMBASE, Cochrane Plus Library and ISI Web of Knowledge with no restrictions on study design or language. Given that some of the studies combined PM and DM patients as research subjects while others included only DM patients, data were subjected to meta-analyses for all combined PM/DM studies and studies that included only DM patients to obtain informative results...
2014: PloS One
Jean-Christophe Lega, Nicole Fabien, Quitterie Reynaud, Isabelle Durieu, Stéphane Durupt, Marine Dutertre, Jean-François Cordier, Vincent Cottin
OBJECTIVE: To describe the clinical spectrum associated with aminoacyl-transfer RNA synthetase (ARS) autoantibodies in patients with idiopathic inflammatory myositis defined according to Peter and Bohan's criteria. METHODS: Cohort studies were selected from MEDLINE and Embase up to August 2013. Two investigators independently extracted data on study design, patient characteristics, and clinical features (interstitial lung disease [ILD], fever, mechanic's hands [MH], Raynaud's phenomenon [RPh], arthralgia, sclerodactyly, cancer and dermatomyositis-specific rash) according to the presence of myositis-specific (anti-aminoacyl-transfer RNA synthetase [ARS], anti-signal recognition particle [anti-SRP] and anti-Mi2) and myositis-associated (anti-PM/Scl, anti-U1-RNP and anti-Ku) autoantibodies...
September 2014: Autoimmunity Reviews
Patompong Ungprasert, Promporn Suksaranjit, Ittikorn Spanuchart, Napat Leeaphorn, Nitipong Permpalung
OBJECTIVES: To investigate the risk of coronary artery disease in patients with idiopathic inflammatory myopathies (IIM). METHODS: We conducted a systematic review and meta-analysis of observational studies that reported odds ratios, relative risks, hazard ratios, or standardized incidence ratios comparing the risk of coronary artery disease in patients with IIM versus non-IIM participants. We searched published studies indexed in MEDLINE, EMBASE, and the Cochrane database from inception to December 2013 using the terms "coronary artery disease" OR "coronary heart disease" OR "myocardial infarction" OR "atherosclerosis" combined with the terms "dermatomyositis" OR "polymyositis" OR "Idiopathic inflammatory myopathy...
August 2014: Seminars in Arthritis and Rheumatism
J Wang, G Guo, G Chen, B Wu, L Lu, L Bao
BACKGROUND: Although some features of dermatomyositis (DM) and polymyositis (PM) have been reported as possible prognostic indicators for cancer development, previous studies were small in size and were unable to establish a definitive relationship between neoplasms and DM and PM. OBJECTIVES: To evaluate risk factors for developing malignancies in patients with DM and PM. METHODS: Meta-analysis of the studies reported in the literature was performed to unveil risk factors for developing cancer among patients with DM and PM...
October 2013: British Journal of Dermatology
Zhiyong Chen, Mengshu Cao, Maria Nieves Plana, Jun Liang, Hourong Cai, Masataka Kuwana, Lingyun Sun
OBJECTIVE: To assess the utility of anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody measurement for predicting a risk for developing rapidly progressive interstitial lung disease (RP-ILD) in patients with polymyositis/dermatomyositis (PM/DM). METHODS: A single-center cohort of 64 consecutive Chinese patients with PM/DM was examined. Serum anti-MDA5 antibody was measured by enzyme-linked immunosorbent assay. For meta-analysis, we searched PubMed and the Institute for Scientific Information Web of Knowledge for original studies that measured anti-MDA5 antibodies in patients with PM/DM...
August 2013: Arthritis Care & Research
Alisa N Femia, Ruth Ann Vleugels, Jeffrey P Callen
Dermatomyositis is a specific type of inflammatory myopathy with characteristic cutaneous findings. Patients may have skin disease without clinically apparent muscle disease, but this disorder is best thought of as a systemic process. Therefore, all patients with dermatomyositis skin lesions need appropriate evaluation for muscle disease, esophageal dysfunction, cardiopulmonary disease, and potential internal malignancy. There are many therapies that have been used for patients with dermatomyositis, but most are based upon case series or expert opinion rather than meta-analyses or randomized, placebo-controlled trials...
August 2013: American Journal of Clinical Dermatology
Esther Toledano, Gloria Candelas, Zulema Rosales, Cristina Martínez Prada, Leticia León, Lydia Abásolo, Estíbaliz Loza, Loreto Carmona, Aurelio Tobías, Juan Ángel Jover
INTRODUCTION: Data reporting mortality in rheumatic diseases vary widely. The objective of this systematic review and meta-analysis of published data is to provide an accurate overview of the current risk of mortality in rheumatic diseases. METHODS: Systematic review and meta-analysis of published studies identified by a sensitive search using free text and MeSH synonyms of "mortality" and of "rheumatic diseases", in general and by specific diagnoses. Eligibility criteria were (1) study population with rheumatoid arthritis, systemic lupus erythemathosus, systemic sclerosis, vasculitis, osteoarthritis, osteoporosis, dermatomyositis, or spondyloarthritis; (2) outcome of interest mortality, reported as an standardized mortality ratio (SMR), or easily calculated from data reported; and (3) cohorts or longitudinal observational studies...
November 2012: Reumatología Clinica
Ernesto Trallero-Araguás, Jose Ángel Rodrigo-Pendás, Albert Selva-O'Callaghan, Xavier Martínez-Gómez, Xavier Bosch, Moisés Labrador-Horrillo, Josep Maria Grau-Junyent, Miquel Vilardell-Tarrés
OBJECTIVE: Anti-p155 autoantibody, which was recently described in adult patients with dermatomyositis (DM), seems to be associated with cancer in this population. We performed a systematic review and meta-analysis to ascertain the accuracy of anti-p155 testing for the diagnosis of cancer-associated myositis. METHODS: We searched relevant databases, with no restrictions on study design or language, for original studies that included adult patients with probable/definite DM or amyopathic DM who were evaluated for neoplasm and anti-p155 status...
February 2012: Arthritis and Rheumatism
Adalisa Di Saverio, Ivano Testa
The authors describe the case of a patient with NHL, who had undergone a series of clinical and laboratory investigations for the presence of pain, oedema and functional deficiency of the lower limbs associated with generalized weakness. From the data of the literature in cases of myositis, labelled as paraneoplastic disorders, no histological classification or phenotypic characterization have been provided, with exception of a case diagnosed as K1 positive lymphoma. A meta-analysis of case control studies and cohort of myositis and neoplasia do not show an increased incidence of cancer before a diagnosis of polymyositis (PM), although it seems to be an increased risk following diagnosis...
April 2003: Recenti Progressi in Medicina
N Hajjaji, V Lesire, P Leturgie, B Lafon, J P Renard
INTRODUCTION: Dermatopolymyositis is an inflammatory disorder of an unknown origin. Twenty to thirty percent cases of this disease are associated with a cancer. Glomerular lesions in dermatopolymyositis are rare. EXEGESIS: We describe the case of a patient who presented a dermatopolymyositis together with a glomerulopathy and then a non Hodgkin's lymphoma. A treatment by corticoid and secondary intravenous immune globulins because of corticoid-resistance of the dermatopolymyositis and oesophagus injury led to a significant improvement of the cutaneous signs and of the muscular weakness...
July 2002: La Revue de Médecine Interne
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"